Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Bacillus Cereus Invasive Infections in Preterm Neonates Hospitalized in French Hospitals

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Background. Bacillus cereus group (Bc) comprises twenty-six closely related species of spore-forming environmental bacteria. Recently, increased sepsis and septic shock caused by Bc were reported in preterm neonates (PN), and the mortality rate can reach up to 30%. Using Whole Genome Sequencing (WGS) increasingly used to characterize Bc strains, The team aimed to determine an accurate identification to the species level of the strains involved in Bc invasive infections in preterm neonates in France and study their virulome profile.Methods. The team performed WGS for 40 neonate clinical strains responsible for invasive infections in PN. A screening of virulence genes was performed to characterize strains associated with poor prognosis. Clinical data were collected and all clinical and genomic findings were analyzed for risk factors for death. "

Who May Be Eligible (Plain English)

Who May Qualify: - Premature newborn (i.e born before 37 last menstrual periods) with invasive infection caused by B. cereus (strains isolated from blood culture and cerebrsopinal fluid) Who Should NOT Join This Trial: - None Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Premature newborn (i.e born before 37 last menstrual periods) with invasive infection caused by B. cereus (strains isolated from blood culture and cerebrsopinal fluid) Exclusion Criteria: * None

Treatments Being Tested

BIOLOGICAL

Premature neonates with invasive infection caused by Bacillus cereus

The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.

Locations (13)

CHU NICE
Nice, Alpes Maritimes, France
CHU lille
Lille, France
AP-HM Marseille
Marseille, France
CHU Nantes
Nantes, France
CHU Nîmes
Nîmes, France
AP-HP Hôpital Robert Debré
Paris, France
Hôpital Antoine Béclère, AP-HP
Paris, France
Hôpital Cochin
Paris, France
CHU de Poitiers
Poitiers, France
CHU Rennes
Rennes, France
CHRU de Strasbourg
Strasbourg, France
CHU Toulouse
Toulouse, France
CHU de Tours
Tours, France